Several other analysts also recently issued reports on CRSP. Goldman Sachs Group increased their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a report on Tuesday, November 19th. Wells Fargo & Co reiterated a buy rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Roth Capital increased their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Oppenheimer increased their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a report on Monday, November 25th. Finally, Chardan Capital reiterated a buy rating and issued a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $69.54.
NASDAQ CRSP traded down $0.67 during trading hours on Friday, hitting $65.36. The company had a trading volume of 737,055 shares, compared to its average volume of 1,650,207. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $58.93 and its 200 day moving average is $48.44.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Research analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the business. Nikko Asset Management Americas Inc. lifted its position in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics during the third quarter worth about $21,167,000. Finally, Morgan Stanley lifted its position in shares of Crispr Therapeutics by 6.1% during the second quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after purchasing an additional 16,361 shares during the last quarter. 49.82% of the stock is owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Understanding Average Daily Trade Volume
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.